Camurus AB (publ) (CAMX.ST)
SEK 574.5
(1.77%)
SEK 574.5
(1.77%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 532.35 Million SEK | 639.83% |
| 2022 | 71.95 Million SEK | 164.04% |
| 2021 | -112.35 Million SEK | 45.61% |
| 2020 | -206.56 Million SEK | 42.63% |
| 2019 | -360.08 Million SEK | -25.37% |
| 2018 | -287.21 Million SEK | -17.94% |
| 2017 | -243.52 Million SEK | -137.7% |
| 2016 | -102.45 Million SEK | 49.8% |
| 2015 | -204.1 Million SEK | -427.51% |
| 2014 | 62.31 Million SEK | -51.05% |
| 2013 | 127.31 Million SEK | 578.62% |
| 2012 | 18.76 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 79 Million SEK | 572.09% |
| 2024 Q2 | 84.84 Million SEK | 7.4% |
| 2023 Q3 | 104.04 Million SEK | -72.33% |
| 2023 Q1 | 74.33 Million SEK | 293.74% |
| 2023 FY | 532.35 Million SEK | 639.83% |
| 2023 Q4 | -16.73 Million SEK | -116.08% |
| 2023 Q2 | 376.06 Million SEK | 405.9% |
| 2022 Q4 | 18.87 Million SEK | -54.37% |
| 2022 Q1 | 4.79 Million SEK | 126.4% |
| 2022 Q2 | 6.91 Million SEK | 44.33% |
| 2022 Q3 | 41.37 Million SEK | 498.28% |
| 2022 FY | 71.95 Million SEK | 164.04% |
| 2021 Q4 | -18.15 Million SEK | -187.87% |
| 2021 Q2 | -59.78 Million SEK | -127.04% |
| 2021 Q1 | -26.33 Million SEK | 67.73% |
| 2021 FY | -112.35 Million SEK | 45.61% |
| 2021 Q3 | -6.3 Million SEK | 89.45% |
| 2020 Q3 | -23.39 Million SEK | -0.3% |
| 2020 Q4 | -81.59 Million SEK | -248.81% |
| 2020 FY | -206.56 Million SEK | 42.63% |
| 2020 Q1 | -76.92 Million SEK | 12.99% |
| 2020 Q2 | -23.32 Million SEK | 69.68% |
| 2019 Q1 | -84.43 Million SEK | 18.18% |
| 2019 Q3 | -77.38 Million SEK | 29.53% |
| 2019 FY | -360.08 Million SEK | -25.37% |
| 2019 Q2 | -109.8 Million SEK | -30.05% |
| 2019 Q4 | -88.41 Million SEK | -14.25% |
| 2018 Q4 | -103.18 Million SEK | -82.82% |
| 2018 FY | -287.21 Million SEK | -17.94% |
| 2018 Q3 | -56.44 Million SEK | 30.45% |
| 2018 Q2 | -81.15 Million SEK | -74.8% |
| 2018 Q1 | -46.42 Million SEK | 29.73% |
| 2017 FY | -243.52 Million SEK | -137.7% |
| 2017 Q4 | -66.07 Million SEK | 1.58% |
| 2017 Q3 | -67.13 Million SEK | -14.33% |
| 2017 Q2 | -58.72 Million SEK | -13.83% |
| 2017 Q1 | -51.58 Million SEK | -46.82% |
| 2016 Q2 | -25.88 Million SEK | -4.12% |
| 2016 Q3 | -16.57 Million SEK | 35.95% |
| 2016 Q4 | -35.13 Million SEK | -111.96% |
| 2016 FY | -102.45 Million SEK | 49.8% |
| 2016 Q1 | -24.85 Million SEK | 38.5% |
| 2015 Q1 | 13.1 Million SEK | -86.43% |
| 2015 Q2 | -147.64 Million SEK | -1226.55% |
| 2015 Q3 | -29.14 Million SEK | 80.26% |
| 2015 Q4 | -40.41 Million SEK | -38.65% |
| 2015 FY | -204.1 Million SEK | -427.51% |
| 2014 FY | 62.31 Million SEK | -51.05% |
| 2014 Q4 | 96.6 Million SEK | 5087.4% |
| 2014 Q3 | -1.93 Million SEK | 0.0% |
| 2013 FY | 127.31 Million SEK | 578.62% |
| 2012 FY | 18.76 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 313.812% |
| Ziccum AB (publ) | -21.56 Million SEK | 2569.179% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | 3345.869% |
| BioArctic AB (publ) | 252.64 Million SEK | -110.717% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | 63100.592% |
| Mendus AB (publ) | -100.65 Million SEK | 628.917% |
| Genovis AB (publ.) | 54.22 Million SEK | -881.77% |
| Intervacc AB (publ) | -93.57 Million SEK | 668.883% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | 3531.891% |
| Active Biotech AB (publ) | -46.48 Million SEK | 1245.244% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | -2856.05% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 1060.635% |
| Aptahem AB (publ) | -10.1 Million SEK | 5368.359% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 265.582% |
| Kancera AB (publ) | -65.04 Million SEK | 918.479% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 495.459% |
| Fluicell AB (publ) | -26.87 Million SEK | 2080.561% |
| Saniona AB (publ) | -81.06 Million SEK | 756.701% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | 4403.25% |
| Biovica International AB (publ) | -126.07 Million SEK | 522.259% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 1352.453% |
| AcouSort AB (publ) | -17.48 Million SEK | 3144.29% |
| Xintela AB (publ) | -57.23 Million SEK | 1030.073% |
| Abliva AB (publ) | -96.54 Million SEK | 651.389% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 263.902% |
| Karolinska Development AB (publ) | -3.5 Million SEK | 15288.445% |
| OncoZenge AB (publ) | -15.9 Million SEK | 3447.724% |
| Amniotics AB (publ) | -29.07 Million SEK | 1931.098% |
| 2cureX AB (publ) | -36.36 Million SEK | 1564.002% |
| CombiGene AB (publ) | -36.3 Million SEK | 1566.334% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | 3736.305% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 238.491% |
| Corline Biomedical AB | -1.78 Million SEK | 29873.77% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 394.501% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 1377.151% |
| I-Tech AB | 24.43 Million SEK | -2078.658% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 167.515% |
| Cyxone AB (publ) | -21.66 Million SEK | 2557.666% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 602.388% |
| Biosergen AB | -27.26 Million SEK | 2052.522% |
| Cantargia AB (publ) | -290.01 Million SEK | 283.56% |
| NextCell Pharma AB | -43.17 Million SEK | 1333.099% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 394.501% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 3213.865% |
| Nanologica AB (publ) | -69.96 Million SEK | 860.909% |
| SynAct Pharma AB | -224.49 Million SEK | 337.133% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 1305.077% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 2322.381% |
| LIDDS AB (publ) | -40.67 Million SEK | 1408.834% |
| Lipum AB (publ) | -37.25 Million SEK | 1528.987% |
| BioInvent International AB (publ) | -369.94 Million SEK | 243.902% |
| Alzinova AB (publ) | -16.52 Million SEK | 3322.098% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 310.046% |
| Pila Pharma AB (publ) | -6.39 Million SEK | 8426.83% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 562.624% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 2743.403% |
| Simris Alg AB (publ) | -36.63 Million SEK | 1553.132% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 463.216% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 271.492% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 579.971% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | 4702.758% |